Related Experiment Video
Updated: May 8, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Biosimilars: part 2: potential concerns and challenges for p&t committees.
P & T : a Peer-Reviewed Journal for Formulary Management
|August 16, 2013
Summary
Pharmacy and Therapeutics (P&T) committee members require comprehensive data to assess biosimilar products. This information is crucial for evaluating efficacy, safety, interchangeability, and cost-effectiveness before formulary inclusion.
Area of Science:
- Pharmacoeconomics
- Health Policy
- Drug Development
Background:
- Biosimilar products offer potential cost savings but require rigorous evaluation.
- Pharmacy and Therapeutics (P&T) committees play a critical role in formulary decision-making.
- Current information may be insufficient for comprehensive biosimilar assessment.
Purpose of the Study:
- To identify the information needs of P&T committee members regarding biosimilar products.
- To guide the development of comprehensive evaluation frameworks for biosimilars.
Main Methods:
- Literature review of P&T committee guidelines.
- Analysis of expert recommendations on biosimilar evaluation.
- Survey of P&T committee member information requirements.
Main Results:
- P&T members need detailed data on clinical efficacy and safety profiles.
- Information on biosimilar interchangeability with reference products is essential.
- Cost-effectiveness analyses are critical for formulary placement decisions.
Conclusions:
- Enhanced data submission requirements are necessary for biosimilar evaluation.
- Standardized information frameworks will support P&T committee decision-making.
- Addressing information gaps will facilitate the appropriate integration of biosimilars into healthcare formularies.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:19Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...